Videos
Increasing M&A deals and cutting edge therapies are driving biotech ETFs higher.

IShares Nasdaq Biotechnology ETF: https://www.zacks.com/funds/etf/IBB/profile?cid=CS-YOUTUBE-FT-VID
SPDR S&P Biotech ETF: https://www.zacks.com/funds/etf/XBI/profile?cid=CS-YOUTUBE-FT-VID
ARK Genomic Revolution ETF: https://www.zacks.com/funds/etf/ARKG/profile?cid=CS-YOUTUBE-FT-VID
Virtus LifeSci Biotech Clinical Trials ETF: https://www.zacks.com/funds/etf/BBC/profile?cid=CS-YOUTUBE-FT-VID
ALPS Medical Breakthroughs ETF: https://www.zacks.com/funds/etf/SBIO/profile?cid=CS-YOUTUBE-FT-VID
Merck: https://www.zacks.com/stock/quote/MRK?cid=CS-YOUTUBE-FT-VID
Biogen: https://www.zacks.com/stock/quote/BIIB?cid=CS-YOUTUBE-FT-VID
Sanofi: https://www.zacks.com/stock/quote/SNY?cid=CS-YOUTUBE-FT-VID
ArQule: https://www.zacks.com/stock/quote/ARQL?cid=CS-YOUTUBE-FT-VID
Synthorx: https://www.zacks.com/stock/quote/THOR?cid=CS-YOUTUBE-FT-VID

Follow us on StockTwits: http://stocktwits.com/ZacksResearch
Follow us on Twitter: https://twitter.com/ZacksResearch
Like us on Facebook: https://www.facebook.com/ZacksInvestmentResearch

Articles You May Like

Arizona town’s approval of bonds challenged in court
NAFOA changes leadership, plans push on bond bill
Nine killed and thousands injured as Hizbollah pagers explode in Lebanon
Berkshire unloads another chunk of Bank of America as CEO Moynihan lauds Buffett as great shareholder
This 38-year-old is financially independent with passive income. Here’s how he built a 7-figure real estate portfolio